Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PCRX | Common Stock | Options Exercise | $209K | +7K | +5.08% | $29.90 | 145K | May 11, 2023 | Direct | |
transaction | PCRX | Common Stock | Sale | -$210K | -5.02K | -3.47% | $41.78 | 140K | May 11, 2023 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PCRX | Stock Option (Right to Buy) | Options Exercise | $0 | -7K | -100% | $0.00* | 0 | May 11, 2023 | Common Stock | 7K | $29.90 | Direct | F2 |
Id | Content |
---|---|
F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.75 to $41.85, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
F2 | The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 12, 2013. |